Genmab — December 2025
-
Det er stærke data fra EPCORE FL-1-studie. De demonstrerer klare kliniske fordele ved epcoritamab i kombination med rituximab og lenalidomid (R²) sammenlignet med R² alene som standardbehandling for patienter med relapsed/refractory FL efter mindst én tidligere linje. Sikkerhedsprofilen er håndterbar og i tråd med monoterapi.Samlet set balancerer sikkerheden de høje effektresultater godt, hvilket gør behandlingen velegnet til udsatte patienter uden at kompromittere livskvalitet markant.
-
Kan være game changer i relapsed FL. Det ligner en potentiel ny standard i anden linje
Epkinly + R² er markant bedre og længerevarende effekt med acceptabel sikkerhed.
-
Godmorgen
-
Genmab viser lovende resultater i fase 3-studie med kræftmiddel https://proinvestor.com/investornyt/1390915/genmab-viser-lovende-resultater-i-fase-3-studie-med-kraeftmiddel
-
Fra MW "Genmab har fået hævet sit kursmål til 2050 kr. fra 1650 kr. hos JP Morgan.
I samme ombæring fastholdes anbefalingen "neutral", det fremgår af data fra Bloomberg News.
Fredag faldt Genmab-aktien med 1,5 pct. til 2032 kr. Samlet er aktien i Genmab steget 36,2 pct. i år."
-
#ASH25 | PRESENTATION
Lori Leslie shares 3-year results from the phase Ib/II EPCORE NHL-2 trial, of 1L epcoritamab with rituximab + lenalidomide (Arm 6; n = 41) and epcoritamab maintenance monotherapy following SOC (Arm 7; n = 19), in patients with FL. https://x.com/lymphomahub/status/1997759594098295276 -
December 7, 2025
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma https://www.ajmc.com/view/epcore-fl-1-adding-epcoritamab-to-r2-delivers-new-benchmark-in-second-line-follicular-lymphoma -
Genmab gør et godt helhedsindtryk med sine studiedata mener Jyske Bank https://proinvestor.com/investornyt/1390946/genmab-gor-et-godt-helhedsindtryk-med-sine-studiedata-mener-jyske-bank
-
RedirecTT-1 Talquetamab (GPRC5D) + Teclistamab (BCMA) - Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab - https://www.nejm.org/doi/full/10.1056/NEJMoa2514752 https://x.com/DrRishabhOnco/status/1997930035827929089
-
for those that didn't read genmab's press release, the FL data was also published in the Lancet - Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext
-
Genmab Announces New Data from Phase 1b/2 EPCORE
CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) https://proinvestor.com/investornyt/1391260/genmab-announces-new-data-from-phase-1b-2-epcore-cll-1-highlighting-potential-of-epcoritamab-as-monotherapy-and-in-combination-for-patients-with-richter-transformation-rt -
Genmabs kræftmiddel viser opmuntrende resultater mod Richter transformation https://proinvestor.com/investornyt/1391335/genmabs-kraeftmiddel-viser-opmuntrende-resultater-mod-richter-transformation
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind